• Skip to main content
  • Skip to primary sidebar

Biotech Briefings

  • Home
  • About
  • Editors
  • Topics
  • Subscribe
  • Home
  • About
  • Editors
  • Topics
  • Subscribe

Key Takeaways: Life Sciences 2025 Outlook: Capital Markets Webcast (March 19)

March 24, 2025 | Posted by Ryan A. Murr; Branden C. Berns; Melanie E. Neary; Anika Gidwani Topic(s): Capital Markets; Trends and Insights

Melanie Neary, Branden Berns, and Ryan Murr of Gibson Dunn, along with Bud O’Hara of Jefferies, hosted a Life Sciences 2025 Outlook: Capital Markets webcast on Wednesday, March 19, 2025, breaking down capital market trends, deal activity, and industry expectations for life sciences in 2025.

In addition to providing a recap of 2024 transactions, panelists discussed how 2025 market performance and deal activity compare to initial expectations for the year. Panelists discussed timely topics such as:

  • SEC and the New Administration – How potential regulatory shifts could impact capital formation
  • Biotech Valuations – Trends in market cap and enterprise value, plus their ripple effects
  • Deal Structures in Volatile Markets – Why PIPE transactions and reverse mergers can provide stability in otherwise choppy markets

Please visit https://www.gibsondunn.com/webcast-life-sciences-2025-outlook-webcast-series-capital-markets for a recording of the webcast as well as a copy of the slides.

Thanks to Jefferies for joining us for this webcast.

Share:

Primary Sidebar

Gibson Dunn Life Sciences
2025 Outlook Webcast Series
Capital Markets: Click here to view the video recording and program materials.
Royalty Finance: Click here to view the video recording and program materials.
Read ROYALTY REPORT here.

Topics

Capital Markets

Clinical Trials

CVR Spinoff

CVRs

Delaware Law

ECVC

False Claims Act

FDA

FDA Guidance

Government Regulation

International Trade

IPOs

M&A

Manufacturing

Reverse Mergers

Royalty Finance

SEC Updates

Securities Litigation

Shareholder Activism

Trends and Insights

Editors

Rachel Baron

Branden C. Berns

Lindsay Bernsen Wardlaw

Aaron K. Briggs

Gustav W. Eyler

Hui Fang

Carlo Felizardo

Mark Goldman

Charlotte Jacobsen

Jin Hee Kim

Wynne Leahy

Jeff Lombard

Jane M. Love, Ph.D.

Mary Beth Maloney

Katlin McKelvie

James Moloney

Ryan A. Murr

Melanie E. Neary

John D.W. Partridge

Jonathan Phillips

Lindsey D. Schmidt

Samantha Sewall

Sam Shapiro

Adam Smith

Karen A. Spindler

Eric J. Stock

Hong Tran

Todd J. Trattner

Stephen Weissman

Useful Links

  • Gibson Dunn Website
  • Gibson Dunn Life Sciences Landing page
  • Securities Regulation and Corporate Governance Monitor
  • NVCA Model Legal Documents
  • Royalty Finance Tracker
  • Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024
  • IPO Resource Center
  • IP Disputes and Litigation

Archives

Subscribe to Updates
RSS Feed
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved.